125 related articles for article (PubMed ID: 27207419)
1. Bioengineering factor Xa to treat bleeding.
Camire RM
Thromb Res; 2016 May; 141 Suppl 2():S31-3. PubMed ID: 27207419
[TBL] [Abstract][Full Text] [Related]
2. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.
Ivanciu L; Toso R; Margaritis P; Pavani G; Kim H; Schlachterman A; Liu JH; Clerin V; Pittman DD; Rose-Miranda R; Shields KM; Erbe DV; Tobin JF; Arruda VR; Camire RM
Nat Biotechnol; 2011 Oct; 29(11):1028-33. PubMed ID: 22020385
[TBL] [Abstract][Full Text] [Related]
3. Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity.
Ivanciu L; Camire RM
Blood; 2015 Jul; 126(1):94-102. PubMed ID: 25896653
[TBL] [Abstract][Full Text] [Related]
4. Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding.
Thalji NK; Camire RM
Curr Opin Hematol; 2017 Sep; 24(5):453-459. PubMed ID: 28692575
[TBL] [Abstract][Full Text] [Related]
5. Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L).
George LA; Thalji NK; Raffini LJ; Gimotty PA; Camire RM
J Thromb Haemost; 2015 Sep; 13(9):1694-8. PubMed ID: 26190406
[TBL] [Abstract][Full Text] [Related]
6. Targeting TFPI for hemophilia treatment.
Peterson JA; Maroney SA; Mast AE
Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutics for hemophilia and other bleeding disorders.
Callaghan MU; Sidonio R; Pipe SW
Blood; 2018 Jul; 132(1):23-30. PubMed ID: 29769259
[TBL] [Abstract][Full Text] [Related]
8. Procoagulant activity of reversibly acylated human factor Xa.
Wolf DL; Lin PH; Hollenbach S; Wong A; Phillips DR; Sinha U
Blood; 1995 Dec; 86(11):4153-7. PubMed ID: 7492772
[TBL] [Abstract][Full Text] [Related]
9. Reversible acylation of factor Xa as a potential therapy for hemophilia.
Lin PH; Laibelman AM; Sinha U
Thromb Res; 1997 Nov; 88(4):365-72. PubMed ID: 9526960
[TBL] [Abstract][Full Text] [Related]
10. Serpins, New Therapeutic Targets for Hemophilia.
Aymonnier K; Kawecki C; Arocas V; Boulaftali Y; Bouton MC
Thromb Haemost; 2021 Mar; 121(3):261-269. PubMed ID: 32987444
[TBL] [Abstract][Full Text] [Related]
11. New coagulant agent (ankaferd blood stopper) for open hemorrhages in hemophilia with inhibitor.
Öner AF; Doğan M; Kaya A; Sal E; Bektaş MS; Yesilmen O; Ayhan H; Acikgoz M
Clin Appl Thromb Hemost; 2010 Dec; 16(6):705-7. PubMed ID: 19528064
[TBL] [Abstract][Full Text] [Related]
12. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
Hoffman M; Monroe DM
Dis Mon; 2003 Jan; 49(1):14-21. PubMed ID: 12525825
[TBL] [Abstract][Full Text] [Related]
13. Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent.
Ebert M; Raquet E; Schweisgut S; Schmidt PM; Weimer T
Blood Cells Mol Dis; 2021 Jul; 89():102570. PubMed ID: 33962291
[TBL] [Abstract][Full Text] [Related]
14. Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.
Verhoef D; Visscher KM; Vosmeer CR; Cheung KL; Reitsma PH; Geerke DP; Bos MHA
Nat Commun; 2017 Sep; 8(1):528. PubMed ID: 28904343
[TBL] [Abstract][Full Text] [Related]
15. [Guidelines for the treatment of hemophilia].
Meili EO; Blättler W; Jacky E; Schneider W; Kaufmann L; Sigg P; Frick PG
Ther Umsch; 1979 Apr; 36(4):345-58. PubMed ID: 313084
[No Abstract] [Full Text] [Related]
16. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
[TBL] [Abstract][Full Text] [Related]
17. Innovations in coagulation: improved options for treatment of hemophilia A and B.
Pabinger-Fasching I; Pipe S
Thromb Res; 2013 Mar; 131 Suppl 2():S1. PubMed ID: 23537720
[No Abstract] [Full Text] [Related]
18. Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.
Persson E
Thromb Res; 2012 May; 129 Suppl 2():S51-3. PubMed ID: 22405049
[TBL] [Abstract][Full Text] [Related]
19. Polyphosphate as a general procoagulant agent.
Smith SA; Morrissey JH
J Thromb Haemost; 2008 Oct; 6(10):1750-6. PubMed ID: 18665922
[TBL] [Abstract][Full Text] [Related]
20. Bioengineered factor Xa as a potential new strategy for hemophilia therapy.
Camire RM
Expert Rev Hematol; 2012 Apr; 5(2):121-3. PubMed ID: 22475278
[No Abstract] [Full Text] [Related]
[Next] [New Search]
